EP0405988B1 - Utilisation de la superoxide dismutase dans des essais impliquant une oxidase - Google Patents

Utilisation de la superoxide dismutase dans des essais impliquant une oxidase Download PDF

Info

Publication number
EP0405988B1
EP0405988B1 EP90307107A EP90307107A EP0405988B1 EP 0405988 B1 EP0405988 B1 EP 0405988B1 EP 90307107 A EP90307107 A EP 90307107A EP 90307107 A EP90307107 A EP 90307107A EP 0405988 B1 EP0405988 B1 EP 0405988B1
Authority
EP
European Patent Office
Prior art keywords
oxidase
superoxide
antigen
substrate
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP90307107A
Other languages
German (de)
English (en)
Other versions
EP0405988A2 (fr
EP0405988A3 (en
Inventor
Takashi C/O Sankyo Company Ltd. Ikegami
Yoshihiro C/O Sankyo Company Ltd. Sato
Koichi C/O Sankyo Company Ltd. Sekiya
Yukio C/O Sankyo Company Ltd. Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of EP0405988A2 publication Critical patent/EP0405988A2/fr
Publication of EP0405988A3 publication Critical patent/EP0405988A3/en
Application granted granted Critical
Publication of EP0405988B1 publication Critical patent/EP0405988B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase

Definitions

  • the present invention relates to assays involving the deteotion of peroxide.
  • Enzyme assays may be used to detect a substrate whose reaction products may be quantitatively detected.
  • assays are of an extremely limited nature, as the enzyme is specific for only one substrate, or type of substrate. If it is a type of substrate, then there can be no way of knowing which particular substrate has been detected. If it is a single substrate, then the assay is limited to detecting that substrate and no other, so that this sort of assay cannot be generally applied, as there are few substrates which lend themselves to a specific enzyme reaction that produces a readily assayed product.
  • assay Another form of assay is the immunoassay, which involves generating antibodies, preferably monoclonal antibodies for greater specificity, to bind the target antigen. The assay then involves some method of assaying bound antibody, and the most accurate to date has been to label the antibody with a radioisotope, or else to label another antibody directed against either the first antibody or the antigen, in a similar manner. Fluorescent labelling of one of the antibodies is one known technique. Among other problems, techniques which involve labelling of the antibody frequently require assaying the label in situ .
  • Radioimmunoassays additionally suffer from other disadvantages, primarily due to the essential use of radioisotopes.
  • the additional disadvantages include: potential radiation damage to the patient; risk of environmental pollution; the requirement for special devices or facilities for prevention of radioisotope diffusion; costly apparatus; costly reagents; the necessity for qualified staff to handle radioisotopes; the general inconvenience of treatment; and transportation or preservation of the radioisotopes, due to their general instability.
  • An enzyme immunoassay has the potential to be a highly sensitive and powerful diagnostic technique. The technique is based both on the antigen-antibody reaction, which in itself is very specific and which still occurs even when there are only small amounts of antigen, and also on the great sensitivity and specificity of the enzyme/substrate catalytic interaction, but without the restriction of being limited to a particular substrate for the enzyme.
  • the antibody binds the relevant antigen, which need not be an enzyme substrate at all, and the enzyme, which is linked to the antibody, is allowed to react with its own substrate, after excess antibody has been removed.
  • Enzyme immunoassays have now been developed to the extent that their sensitivity and accuracy are frequently equal to or higher than that of radioimmunoassays.
  • enzymes especially intracellular enzymes, are products of nature designed to function in a highly regulated environment, where resistance to denaturing, or otherwise deleterious factors, is either totally unnecessary, or is not a prime requisite.
  • this highly regulated environment is also highly complex and, although it is usually possible to ascertain which components are the most important in the regulation and activity of any one enzyme, the totality of the factors affecting the enzyme can only be deduced empirically.
  • the usefulness of enzymes from the point of view of sensitivity is tempered by the delicacy with which they must be handled and the conditions under which they will operate.
  • the desired enzyme may be somewhat unstable and subject to inactivation when used in enzyme immunoassay, and its activity may be affected dramatically by such factors as pH, temperature, reaction time and other factors, all of which may interfere with the reaction system, and any or all of which may affect the results of the assay and which, if not catered for, can lead to unpredictable and unrepeatable results being obtained.
  • the usefulness of the technique may be severely compromised.
  • Absorption spectrophotometry is the method most frequently employed for the determination of enzyme activity in enzyme immunoassays. If high sensitivity is required, fluorimetry or chemiluminescence methods may be employed. However, when using such sensitive methods, the greater sensitivity can often lead to serious problems being encountered in obtaining accurate and reliable luminescent intensity readings, integrated over time, for the base solution of enzymatic substrate (reagent blank) at low concentrations.
  • the reliable detection limit at low concentrations is determined by the ability to extrapolate the curve generated by higher readings into these regions, or else to take reliable measurements at these concentrations. Neither method is possible where the degree of variation in the background cannot be predicted from one system to another, or where an unknown feature of the background swamps the low readings.
  • the particular problem with the latter instance is one of quantity. In general, where readings are taken of substances occurring in relatively high concentrations, there will not be many factors present in sufficient quantity to affect the reading. Any such factors as may be able to affect the readings will usually be readily identifiable, and can either be eliminated from the system, or allowances built in to the readings. Making allowances is the less desirable of the two, as the presence of a large amount of an adverse factor will greatly complicate readings of the desired substrate when the substrate is present in only low concentrations.
  • oxidase group of enzymes are useful in labelling, because they produce hydrogen peroxide as a result of their interaction with the substrate.
  • the resultant hydrogen peroxide may be determined by, for example, chemiluminescence, but the reliability of the results, especially at low concentrations, may be severely compromised, owing to the background variation of the integrated luminescent intensity of the reagent blank, which can vary from preparation to preparation with little or no predictability, being high on one occasion and low on another occasion all because, for example, it is clear one day and rainy the next.
  • the resulting scatter can seriously hamper research and analysis, and has limited the use of oxidase-labelled immunoassays.
  • EP 186 134 discloses that addition of SOD when performing methods for determining a substance involving an oxidase which catalyses the production of hydrogen peroxide and a chromogenic substrate (for the purpose of colourimetric determination) results in enhanced sensitivity and reliability.
  • the present invention provides, in a first aspect, an oxidase assay system, wherein any background superoxide has been reduced or eliminated.
  • Reduction or elimination of superoxide is preferably achieved by the use of the enzyme superoxide dismutase, which has a particularly surprising enhancing effect on the sensitivity of the assays of the invention when peroxide is present at only low concentrations.
  • the oxidase is not used in conjunction with a chromogenic substrate.
  • One advantage of the present invention lies, for example, in the provision of an oxidase assay system which is accurately and reliably sensitive to low levels of substrate. Another advantage lies in the provision of an enzyme assay system wherein background levels of activity are reduced to allow greater sensitivity of detection.
  • a further advantage lies in the provision of oxidase assay systems with enhanced sensitivity which use only cheap and readily available components.
  • the enzyme immunoassays of the present invention have enhanced sensitivity and are more sensitive to low levels of substrate.
  • Any suitable enzyme assay system may be employed for the purposes of the present invention.
  • assay systems wherein peroxide is detected are most preferred, and the invention also provides an assay system wherein peroxide is measured and any background superoxide has been reduced or eliminated.
  • an assay system using essentially only an oxidase will not generally be for highly sensitive analysis of samples, and so the use of superoxide dismutase will not generally be required for such systems, although the use of superoxide dismutase may be of assistance in such cases, and forms a part of the present invention. Accordingly, it is most preferred to apply the present invention to enzyme immunoassays employing an oxidase label, as these are frequently used in conditions where high sensitivity is important.
  • background superoxide refers to that superoxide present in any component of the assay system which may interfere with the assay, for example, which may affect the reading of peroxide.
  • the relevant component will generally be the sample, although superoxide may occur in one or more other components, depending on the system used, and it may be advantageous to add superoxide dismutase to any or all fractions or components in order to obtain the best results.
  • Superoxide radicals can be formed not only by various kinds of enzymes in vivo but also by radiation, such as ultraviolet or visible light.
  • superoxide radicals may be formed by contact between the substrate and oxygen, when the substrate solution is prepared.
  • the superoxide radicals react with the luminescence reagent to give high readings, making the detection limit at low concentrations subject to increased variability.
  • Superoxide may be reduced or eliminated by any appropriate method known in the art, provided that it does not adversely affect the reagents or leaves residues that substantially affect the assay results. Prime among these is the use of superoxide dismutase, an enzyme produced by most organisms. Superoxide dismutase is readily available and cheap to produce. For the purposes of this specification, reference to superoxide dismutase also includes reference to any other suitable superoxide-removing agent as appropriate.
  • Superoxide dismutase is particularly preferred for use with the present invention, as it has a surprisingly high enhancing effect on luminescent readings, making accurate detection of peroxide possible at an order of magnitude or more lower than was possible in the art, reducing the margin of error and making the linearity of the calibration curve at low concentrations considerably more reliable.
  • the present invention allows greater accuracy of measurement at low concentrations.
  • Superoxide dismutase may be added at any suitable stage to the assay system, but is preferably added to the sample before the assay. Superoxide dismutase may be added to the enzyme-labeled component, but this will generally allow the enzyme less time to act to reduce superoxide levels before levels of peroxide are measured. It will be appreciated that superoxide dismutase may be added to any component of the system in addition to being added to the sample. For best results, the only particular requirement is that superoxide dismutase should be used in such a way that superoxide can be reduced or eliminated before peroxide is measured.
  • peroxide peroxide and the measurement thereof, it will be understood that this reference is to any system to which the present invention may be applied.
  • an enzyme is employed which catalyses a reaction leading to the production of specified levels of peroxide which can be assayed to give a quantitative indication of the amount of substance to be assayed.
  • the present invention is particularly suitable for use with enzyme immunoassay systems, which have previously only been limited in their sensitivity by the unreliability of the calibration curves at low concentrations.
  • the background reading of a reagent sample may be, say, 1 ⁇ Asec but, after addition of superoxide dismutase, this can drop to about 0.07 ⁇ Asec.
  • superoxide dismutase disproportionates superoxide to yield molecular oxygen and assayable peroxide, it might be expected that, on treatment with superoxide dismutase, the background reading might drop by as much as 50% (assuming no original peroxide), but no further.
  • the background reading can level out substantially below this, and drop to as low as 1/30 of the original reading, or even further.
  • the effect of superoxide dismutase is particularly surprising, and would not have been expected to provide such a useful tool in the assays of the invention. It is possible that the effect of superoxide dismutase comes about because superoxide is being continually produced and so the enzyme is not functioning in a one-off capacity, but this explanation seems unlikely.
  • 'reducing or eliminating' is meant causing a reduction in the background level of superoxide prior to or during measurement of peroxide.
  • the reduction may be complete (elimination) but will generally be in the range of about 25-98%, preferably about 50-96%, and more preferably about 65-93% lower than the background level of superoxide. Levels outside of the broadest range tend not to be useful for practical purposes. If superoxide is not reduced by at least about 25%, then the increased accuracy of the assay is unlikely to be of great statistical significance and so not worth any extra expenditure of effort or materials. Reduction by greater than about 98% involves increasing amounts of superoxide dismutase to increasingly little effect, although it will be appreciated that reduction by 100% is technically desirable.
  • the blank value will generally remain effectively stable and the solution remains useable for up to 12 months or more.
  • the present invention also provides an assay technique as described above wherein background superoxide is reduced or eliminated.
  • the technique is as described in claims 11 to 13 hereinafter.
  • the invention provides an enzyme immunoassay technique which is stabilised and sensitised by the addition of superoxide dismutase.
  • the determination system involves antigen-antibody binding and is assayed quantitatively using a labelling enzyme.
  • any conventional procedures may be employed for the enzyme immunoassay itself. Suitable examples include the procedures wherein: the substance to be assayed (antigen) may be labelled with an oxidase enzyme, then the labelled antigen, together with the antigen in the unlabelled sample, is brought into contact with the corresponding antibody, and a second antibody is used to bind the first, whereafter the immobilised enzyme can be assayed (competitive assay); and, alternatively, the antigen may be allowed to react with the corresponding immobilised antibody, and then an enzyme-labelled anti-antigen antibody is allowed to react with the system and, thereafter, assaying the enzyme (ELISA [enzyme-linked immunosorbent assay] - sandwich assay).
  • the ELISA technique may be conducted essentially as a 'one-step' or 'two-step' assay.
  • the 'one-step' assay involves contacting antigen with immobilised antibody and, without washing, contacting the mixture with labeled antibody.
  • the 'two-step' assay involves washing before contacting the mixture with labeled antibody.
  • Other conventional methods may also be employed as suitable.
  • the substance to be assayed may be any substance exhibiting antigenicity, in particular, physiologically active substances existing in bodily fluids, examples of whioh include serum, plasma, urine and ascites fluid.
  • substances in such fluids which can be assayed include various peptide and steroid hormones, foetal proteins such as ⁇ -foetoprotein and CEA (caroino-embryonic antigen), immunoglobulin, antiviral antibodies and drugs.
  • Enzymatic labelling of the substances and/or their antibodies may be effected by conventional means (cf. Enzyme Immunoassay: published by Igaku Shoin, 1987).
  • Such means will generally include covalent linking of the enzyme to the antigen or the antibody in question, specifically so as not to adversely affect the activity of the enzyme, by which it is meant that the enzyme must still be capable of interacting with its substrate, although it is not necessary for all of the enzyme to be active, provided that enough remains active to permit the assay to be effected.
  • some techniques for binding enzyme are non-specific (such as the use of formaldehyde), and may only yield a proportion of active enzyme.
  • cross-linking may be disadvantageous, however, from the point of view of activity, but may at least preserve some activity if the protein would otherwise dissociate.
  • the labelled antigen be the naturally occurring antigen, or at least the relevant naturally occurring antigen.
  • the BCG antigen would provide a useful substrate for labelling, as it is readily available and safer to use than the naturally occurring antigen.
  • Enzymes which are suitable for labelling are not particularly limited, but are selected from the members of the oxidase group. These enzymes catalyse the production of hydrogen peroxide by reaction with their substrates (suitable examples of substrates are described hereinafter).
  • suitable enzymes include; L-amino acid oxidase, aldehyde oxidase, ethanolamine oxidase, galactose oxidase, xanthine oxidase, glycolate oxidase, glycerol oxidase, glycerol-3-phosphate oxidase, glucose oxidase.
  • D-glutamate oxidase D-glutamate oxidase, cholesterol oxidase, dihydroorotate oxidase, oxalate oxidase, tyramine oxidase, L-2-hydroxylate oxidase, pyridoxine phosphate oxidase, pyruvate oxidase, putrescine oxidase, hexose oxidase, lathosterol oxidase and lysine ⁇ -oxidase.
  • glucose oxidase is frequently used for its stability, ease of availability and cheapness.
  • Activity of the enzyme employed for labelling may be assayed by measuring the concentration of hydrogen peroxide formed after reaction of the enzyme-labelled antibody with the substrate under controlled conditions by techniques well-known in the art.
  • Suitable substrates for the above enzymes include; L-leucine, L-methionine, L-alanine, acetaldehyde, purine, hypoxanthine, ethanolamine, D-galactose, lactose, xanthine, glycolic acid, lactic acid, glycerol, dihydroxyacetone, glycerol triphosphate, glucose, D-mannose, D-galactose, D-glutamic acid, orotic acid, D-dihydroorotic acid, oxalic acid, tyramine, dopamine, L-2-hydroxyisocapronic acid, glycolic acid, pyridoxine-5-phosphate, pyruvic acid, putrescine, D-glucose, D-galaotose, lathosterol, L-lysine, L-ornithine and L-phenylalanine. Choice will be determined according to the enzyme employed. For example, if glucose oxidase is selected
  • the concentration of hydrogen peroxide may be assayed, for example, by colorimetry, fluorimetry or chemiluminesoence.
  • appropriate reagents include 1,2-diaminobenzene or 2,2′-amino-bis(3-ethylbenzothiazoline-6-sulphonic acid).
  • Appropriate reagents for fluorimetry include p-hydroxyphenylpropionic acid, tyramine and homovaline.
  • appropriate reagents include luminol, luminol derivatives, oxalate, oxalate derivatives, acridium, pyrogallol and 8-anilinonaphthalene-1-sulphonic acid.
  • An oxidation catalyst such as peroxidase or microperoxidase, is required before any of the above reagents can react with peroxide for the appropriate assay.
  • Superoxide dismutase is a well-known enzyme and has been prepared from both human and bovine erythrocytes. Recently, human recombinant superoxide dismutase has been produced in anticipation of its use as a drug. However, for the purposes of the present invention, the origin of the superoxide dismutase is of no particular relevance, and the enzyme may be prepared from any appropriate source.
  • the amount of superoxide dismutase used is not critical to the present invention, provided that an adequate reduction in superoxide occurs.
  • a concentration of about 10 ⁇ g/ml has been found to be sufficient.
  • Lower concentrations may be used, such as 5 ⁇ g/ml, but much lower concentrations will not reduce levels of superoxide as effectively, while higher concentrations, such as over about 20 ⁇ g/ml, have little extra effect.
  • All of the steps associated with the assays of the invention may be conducted under conditions well-known in the art, particularly with regard to reaction time and temperature.
  • Substrate solutions containing 10 ⁇ g/ml of added recombinant human superoxide dismutase and human erythrocyte superoxide dismutase were each put in a brown bottle and allowed to stand in a dark room at 4°C. The integrated luminescence intensities of the solutions were determined with time.
  • Fig. 4 shows the results obtained, illustrating the change in luminescent intensity with time for substrate solutions using superoxide dismutase from the two sources (SOD-A: human erythrocyte. SOD-B: recombinant gene. + and - mean with and without superoxide dismutase, respectively), the x and y axes representing standing time and integrated luminescence intensity respectively. The results indicated by the solid points represent the controls (no superoxide dismutase).
  • the use of superoxide dismutase in accordance with the present invention enhances assay accuracy at low concentrations and, in addition, the increased temporal stability of substrate solutions containing superoxide dismutase allows storage of these solutions in a useable condition over extended periods of time.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (20)

  1. Système, de préférence système de dosage immuno-enzymatique, comprenant des réactifs pour la détermination d'une quantité d'une substance en solution et comprenant une oxydase qui catalyse la production de peroxyde d'hydrogène dans une quantité proportionnelle à la quantité de substance et des moyens de dosage du peroxyde,
    caractérisé en ce que le système comprend en plus des moyens, de préférence la superoxyde dismutase, pour réduire les niveaux de superoxyde;
    pourvu que l'oxydase ne soit pas utilisée conjointement avec un substrat chromogène.
  2. Système selon la revendication 1, dans lequel l'oxydase contient une ou plusieurs, de préférence une, des enzymes suivantes : la L-amino-acide oxydase, l'adléhyde oxydase, l'éthanolamine oxydase, la galactose oxydase, la xanthine oxydase, la glycolate oxydase, la glycérol oxydase, la glycérol-3-phosphate oxydase, la glucose oxydase, la D-glutamate oxydase, la cholestérol oxydase, la dihydro-orotate oxydase, l'oxalate oxydase, la tyramine oxydase, la L-2-hydroxylate oxydase, la pyridoxine phosphate oxydase, la pyruvate oxydase, la putrescine oxydase, l'hexose oxydase, la lathostérol oxydase et la lysine α-oxydase,
        de préférence la glucose oxydase.
  3. Système immuno-enzymatique pour la détermination d'une quantité d'antigène dans une solution, dans lequel une oxydase est capable de catalyser la production de peroxyde d'hydrogène à partir d'un substrat, le système comprenant le substratetdes moyens de dosage du peroxyde,
    caractérisé en ce que le système comprend en plus des moyens, de préférence la superoxyde dismutase, pour réduire les niveaux de superoxyde;
    pourvu que l'oxydase ne soit pas utilisée conjointement avec un substrat chromogène.
  4. Système selon la revendication 3, dans lequel l'oxydase contient une ou plusieurs, de préférence une, des enzymes suivantes : la L-amino-acide oxydase, l'adléhyde oxydase, l'éthanolamine oxydase, la galactose oxydase, la xanthine oxydase, la glycolate oxydase, la glycérol oxydase, la glycérol-3-phosphate oxydase, la glucose oxydase, la D-glutamate oxydase, la cholestérol oxydase, la dihydro-orotate oxydase, l'oxalate oxydase, la tyramine oxydase, la L-2-hydroxylate oxydase, la pyridoxine phosphate oxydase, la pyruvate oxydase, la putrescine oxydase, l'hexose oxydase, la lathostérol oxydase et la lysine α-oxydase,
        de préférence la glucose oxydase.
  5. Système selon la revendication 4, dans lequel le substrat enzymatique contient l'un ou plusieurs, de préférence l'un, des substrats suivants : la L-leucine, la L-méthionine, la L-alanine, l'acétaldéhyde, la purine, l'hypoxanthine, l'éthanolamine, le D-galactose, le lactose, la xanthine, l'acide glycolique, l'acide lactique, le glycérol, la dihydroxyacétone, le glycéroltriphosphate, le glucose, le D-mannose, le D-galactose, l'acide D-glutamique, l'acide orotique, l'acide D-dihydroorotique, l'acide oxalique, la tyramine, la dopamine, l'acide L-2-hydroxyisocapronique, l'acide glycolique, la pyridoxine-5-phosphate, l'acide pyruvique, la putrescine, le D-glucose, le D-galactose, le lathostérol, la L-lysine, la L-ornithine et la L-phénylalanine
        de préférence le glucose.
  6. Système selon l'une des revendications 3 à 5, dans lequel le système comprend un dosage de type sandwich ou un dosage de type compétitif.
  7. Système selon l'une des revendications 3 à 6, dans lequel les moyens de réduction du superoxyde sont ajoutés à une solution contenant la substance avant le dosage.
  8. Système selon l'une des revendications 3 à 7, dans lequel le moyen de réduction du superoxyde est la superoxyde dismutase, la superoxyde dismutase étant présente en quantité supérieure à environ 5 µg/ml, de préférence supérieure à environ 10 µg/ml.
  9. Système selon l'une des revendications 3 à 8, dans lequel l'enzyme est immobilisée sur un support.
  10. Système selon la revendication 9, dans lequel l'enzyme est liée à un anticorps immobilisé sur le support.
  11. Méthode pour la détermination de la quantité d'un antigène dans une solution en utilisant un système tel que défini dans la revendication 1, comprenant :
    (i) la mise en contact de l'antigène avec un anticorps immobilisé pour cela sur un support ;
    (ii) l'élimination de l'antigène libre ;
    (iii) la mise en contact de l'antigène lié avec un anticorps marqué par une oxydase capable de se fixer à l'antigène lié ;
    (iv) l'élimination de l'anticorps libre marqué par une oxydase ;
    (v) l'introduction d'un substrat de l'oxydase, de manière à permettre ainsi le dosage de l'activité enzymatique,
    et, optionnellement, la répétition d'au moins une des étapes ci-dessus, au moins une fois, l'oxydase étant capable de catalyser la production de peroxyde à partir du substrat, caractérisé en ce que la méthode contient en plus l'utilisation de moyens, de préférence la superoxyde dismutase, pour réduire les niveaux de superoxyde dans au moins une des étapes (i) à (v).
  12. Méthode pour la détermination de la quantité d'un antigène dans une solution en utilisant un système tel que défini dans la revendication 1, comprenant :
    (i) la mise en contact de l'antigène et d'une quantité de l'antigène marqué avec une oxydase, avec un anticorps, et cela pour former un complexe ;
    (ii) la mise en contact du complexe avec un anticorps immobilisé capable de se fixer au complexe ;
    (iii) l'élimination du complexe libre ;
    (iv) l'introduction du substrat de l'oxydase de manière à permettre ainsi le dosage de l'activité enzymatique,
       et, optionnellement, la répétition d'au moins une des étapes ci-dessus, au moins une fois, l'oxydase étant capable de catalyser la production de peroxyde à partir du substrat, caractérisé en ce que la méthode contient en plus l'utilisation de moyens, de préférence la superoxyde dismutase, pour réduire les niveaux de superoxyde dans au moins une des étapes (i) à (iv).
  13. Méthode pour la détermination de la quantité d'un antigène en solution par l'utilisation d'un système tel que défini dans la revendication 1, comprenant :
    (i) la mise en contact de l'antigène avec un anticorps immobilisé pour cela sur un support ;
    (ii) la mise en contact de l'antigène lié avec un anticorps marqué par une oxydase capable de se fixer à l'antigène lié ;
    (iii) l'élimination de l'anticorps libre marqué par une oxydase, de l'antigène libre et du complexe libre (anticorps marqué par une enzyme(/antigène ;
    (iv) l'introduction d'un substrat de l'oxydase de manière à permettre ainsi le dosage de l'activité enzymatique,
    et, optionnellement, la répétition d'au moins une des étapes ci-dessus, au moins une fois, l'oxydase étant capable de catalyser la production de peroxyde à partir du substrat, caractérisé en ce que la méthode contient en plus l'utilisation de moyens de préférence la superoxyde dismutase, pour réduire les niveaux de superoxyde dans au moins une des étapes (i) à (iv).
  14. Méthode selon l'une des revendications 11 à 13, dans laquelle l'oxydase contient une ou plusieurs, de préférence une, des enzymes suivantes : la L-amino-acide oxydase, l'aldéhyde oxydase, l'éthanolamine oxydase, la galactose oxydase, la xanthine oxydase, la glycolate oxydase, la glycérol oxydase, la glycérol-3-phosphate oxydase, la glucose oxydase, la D-glutamate oxydase, la cholestérol oxydase, la dihydro-orotate oxydase, l'oxalate oxydase, la tyramine oxydase, la L-2-hydroxylate oxydase, la pyridoxine phosphate oxydase, la pyruvate oxydase, la putrescine oxydase, l'hexose oxydase, la lathostérol oxydase et la lysine α-oxydase,
        de préférence la glucose oxydase.
  15. Méthode selon la revendication 14, dans laquelle le substrat de l'enzyme contient l'un ou plusieurs, de préférence l'un, des substrats suivants : la L-leucine, la L-méthionine, la L-alanine, l'acétaldéhyde, la purine, l'hypoxanthine, l'éthanolamine, le D-galactose, le lactose, la xanthine, l'acide glycolique, l'acide lactique, le glycérol, la dihydroxyacétone, le glycéroltriphosphate, le glucose, le D-mannose, le D-galactose, l'acide D-glutamique, l'acide orotique, l'acide D-dihydroorotique, l'acide oxalique, la tyramine, la dopamine, l'acide L-2-hydroxyisocapronique, l'acide glycolique, la pyridoxine-5-phosphate, l'acide pyruvique, la putrescine, le D-glucose, le D-galactose, le lathostérol, la L-lysine, la L-ornithine et la L-phénylalanine
        de préférence le glucose.
  16. Méthode selon l'une des revendications 11 à 15, dans laquelle les moyens de réduction du superoxyde sont ajoutés avant que le substrat ne soit ajouté.
  17. Méthode selon la revendication 16, dans laquelle les moyens de réduction du superoxyde sont ajoutés à la solution contenant l'antigène.
  18. Méthode selon l'une des revendications 11 à 17, dans laquelle le moyen de réduction du superoxyde est la superoxyde dismutase, la superoxyde dismutase étant ajoutée en une quantité supérieure à environ 5 µg/ml, de préférence supérieure à environ 10 µg/ml.
  19. Méthode selon l'une des revendications 11 à 18, dans laquelle les moyens de réduction du superoxyde sont utilisés dans la préparation du du réactif témoin.
  20. Méthode pour la sensibilisation d'un dosage dans laquelle de faibles niveaux de peroxyde d'hydrogène produits par une oxydase à partir d'un substrat non chromogène sont détectés, comprenant l'utilisation de moyens, de préférence la superoxyde dismutase, pour réduire les niveaux de superoxyde.
EP90307107A 1989-06-28 1990-06-28 Utilisation de la superoxide dismutase dans des essais impliquant une oxidase Expired - Lifetime EP0405988B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP16625589 1989-06-28
JP166255/89 1989-06-28

Publications (3)

Publication Number Publication Date
EP0405988A2 EP0405988A2 (fr) 1991-01-02
EP0405988A3 EP0405988A3 (en) 1992-04-22
EP0405988B1 true EP0405988B1 (fr) 1996-03-27

Family

ID=15827989

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90307107A Expired - Lifetime EP0405988B1 (fr) 1989-06-28 1990-06-28 Utilisation de la superoxide dismutase dans des essais impliquant une oxidase

Country Status (9)

Country Link
EP (1) EP0405988B1 (fr)
JP (1) JPH0394160A (fr)
AT (1) ATE136060T1 (fr)
CA (1) CA2019711A1 (fr)
DE (1) DE69026147T2 (fr)
DK (1) DK0405988T3 (fr)
ES (1) ES2087892T3 (fr)
GR (1) GR3020057T3 (fr)
HK (1) HK1005748A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU531777B2 (en) * 1978-04-05 1983-09-08 Syva Co. Label/solid conjugate immunoassay system
JPS5632422A (en) * 1979-08-27 1981-04-01 Mochida Pharmaceut Co Ltd Preventive and remedy for disorder caused by active oxygen in living body
JPS61128899A (ja) * 1984-11-26 1986-06-16 Sanko Junyaku Kk 基質又は酵素の測定法
DE3446637A1 (de) * 1984-12-20 1986-07-03 Boehringer Mannheim Gmbh, 6800 Mannheim Mittel zur verbesserung des nachweises h(pfeil abwaerts)2(pfeil abwaerts)0(pfeil abwaerts)2(pfeil abwaerts)-liefernder oxidase-reaktionen und seine verwendung
JPH0779715B2 (ja) * 1987-04-20 1995-08-30 東洋紡績株式会社 Ｎａｄｈ又はｎａｄｐｈのペルオキシダ−ゼによる定量法
JP2515551B2 (ja) * 1987-06-08 1996-07-10 和光純薬工業株式会社 新規な過酸化水素の定量方法
JPH0329854A (ja) * 1989-06-28 1991-02-07 Meidensha Corp 酵素免疫測定方法

Also Published As

Publication number Publication date
GR3020057T3 (en) 1996-08-31
ATE136060T1 (de) 1996-04-15
DE69026147D1 (de) 1996-05-02
EP0405988A2 (fr) 1991-01-02
CA2019711A1 (fr) 1990-12-28
JPH0394160A (ja) 1991-04-18
ES2087892T3 (es) 1996-08-01
DK0405988T3 (da) 1996-07-29
DE69026147T2 (de) 1996-11-21
EP0405988A3 (en) 1992-04-22
HK1005748A1 (en) 1999-01-22

Similar Documents

Publication Publication Date Title
US4016043A (en) Enzymatic immunological method for the determination of antigens and antibodies
US8956823B2 (en) Anti-antibody reagent
Forest et al. Evaluation of the analytical performance of the Boehringer Mannheim Elecsys® 2010 immunoanalyzer
Boitieux et al. An" antibody electrode," preliminary report on a new approach in enzyme immunoassay.
US4686181A (en) Specific binding assay employing anti-G6PDH as label
Schroeder et al. Immunochemiluminometric assay for hepatitis B surface antigen.
Kokado et al. Chemiluminescence assay of alkaline phosphatase using cortisol-21-phosphate as substrate and its application to enzyme immunoassays
US5919642A (en) Competitive binding assays having improved linearity
Galen et al. Enzyme immunoassay of serum thyroxine with the" Autochemist" multichannel analyzer.
Alpha et al. Sensitive amplified immunoenzymometric assays (IEMA) for human insulin and intact proinsulin
Maeda et al. Enzymatic immunoassay of α-fetoprotein, insulin and 17-α-hydroxyprogesterone base on chemiluminescence in a flow-injection system
EP0095089A1 (fr) Méthode de test de fixation homogène, système réactif, nécessaire d'essai et appareil pour la réalisation du test
EP0405988B1 (fr) Utilisation de la superoxide dismutase dans des essais impliquant une oxidase
von Lode et al. One-step quantitative thyrotropin assay for the detection of hypothyroidism in point-of-care conditions
JPH0875748A (ja) 特異結合分析方法および装置
EP1192467B1 (fr) Dosage redox par chimiluminescence en vue de l'evaluation quantitative d'analytes dans des echantillons biologiques
Boitieux et al. A computerised enzyme immunosensor: application for the determination of antigens
JP3228791B2 (ja) 検体中の抗原又は抗体の測定法
EP0125368A1 (fr) Méthode de détection immunologique par potentiométrie de la vitesse de réaction en utilisant une électrode à sélectivité ionique au fluorure
Schroeder Luminescent immunoassay in clinical analysis
EP0345777B1 (fr) Immunoessai
EP0398920A1 (fr) Analyses biochimiques a marquage enzymatique visant a determiner la presence de deux analytes
US4778755A (en) Immunoassay method
Gould et al. Recent developments in enzyme immunoassays
US6455261B1 (en) Diagnostic assay using microperoxidase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19921015

17Q First examination report despatched

Effective date: 19940210

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 136060

Country of ref document: AT

Date of ref document: 19960415

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

REF Corresponds to:

Ref document number: 69026147

Country of ref document: DE

Date of ref document: 19960502

ET Fr: translation filed
ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: BA2A

Ref document number: 2087892

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3020057

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2087892

Country of ref document: ES

Kind code of ref document: T3

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19980609

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 19980612

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19980615

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19980616

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19980619

Year of fee payment: 9

Ref country code: ES

Payment date: 19980619

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19980625

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19980629

Year of fee payment: 9

Ref country code: LU

Payment date: 19980629

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19980706

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19980708

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19980813

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990628

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990628

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990628

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19990629

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990630

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990630

Ref country code: FR

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19990630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990630

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990630

BERE Be: lapsed

Owner name: SANKYO CY LTD

Effective date: 19990630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000101

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19990628

EUG Se: european patent has lapsed

Ref document number: 90307107.4

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20000101

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000503

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20010503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050628